Barbara L. Masecar
- Infectious Diseases top 10%
- Molecular Biology
- Epidemiology
- Molecular Medicine top 5%
- Radiology, Nuclear Medicine and Imaging
- Co-authors
- Jan E. PattersonWalter J. HierholzerM. J. ZervosN J RobillardGeorge A. BaumbachChristopher A. DaddDavid J. HammondMarcus Zervos
- Topics
- Antibiotic Resistance in Bacteria (4 papers)Antibiotics Pharmacokinetics and Efficacy (3 papers)Cancer therapeutics and mechanisms (2 papers)
- Journals
- The Journal of Infectious DiseasesAntimicrobial Agents and ChemotherapyBioorganic & Medicinal Chemistry
- Partner nations
- United StatesAustraliaNetherlands
In The Last Decade
Barbara L. Masecar
11 papers receiving 419 citations
Peers
Comparison fields: 5 of 68
- Infectious Diseases 160
- Molecular Biology 152
- Epidemiology 142
- Molecular Medicine 85
- Radiology, Nuclear Medicine and Imaging 85
Countries citing papers authored by Barbara L. Masecar
This map shows the geographic impact of Barbara L. Masecar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara L. Masecar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara L. Masecar more than expected).
Fields of papers citing papers by Barbara L. Masecar
This network shows the impact of papers produced by Barbara L. Masecar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara L. Masecar. The network helps show where Barbara L. Masecar may publish in the future.
Co-authorship network of co-authors of Barbara L. Masecar
This figure shows the co-authorship network connecting the top 25 collaborators of Barbara L. Masecar. A scholar is included among the top collaborators of Barbara L. Masecar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara L. Masecar. Barbara L. Masecar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 36 | |
| 2 | 47 | |
| 3 | 30 | |
| 4 | 52 | |
| 5 | 49 | |
| 6 | 12 | |
| 7 | 36 | |
| 8 | 71 | |
| 9 | 51 | |
| 10 | 27 | |
| 11 | 45 |
About Barbara L. Masecar
Barbara L. Masecar is a scholar working on Molecular Medicine, Hepatology and Infectious Diseases, having authored 11 papers that have together received 456 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Molecular Medicine (85 citations), Clinical Biochemistry (65 citations) and Infectious Diseases (160 citations). Barbara L. Masecar has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Jan E. Patterson, Walter J. Hierholzer, M. J. Zervos, N J Robillard, George A. Baumbach, Christopher A. Dadd, David J. Hammond, Marcus Zervos, G. Barden and Thomas F. Patterson. Their work appears in journals such as The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and Bioorganic & Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.